<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02110134</url>
  </required_header>
  <id_info>
    <org_study_id>CYN13-REV-TOP-MEL-AK</org_study_id>
    <nct_id>NCT02110134</nct_id>
  </id_info>
  <brief_title>A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma</brief_title>
  <official_title>A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cynosure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cynosure, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare a hydroquinone skin care regimen alone to a
      combination of Revlite Laser treatment with a hydroquinone skin care regimen for the
      treatment of melasma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Photographic Evaluation using the Global Aesthetic Improvement Scale</measure>
    <time_frame>1 month post last treatment</time_frame>
    <description>Photos will be a taken at baseline and post treatment and then improvement assessed using the Global Aesthetic Improvement Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction Questionnaire</measure>
    <time_frame>1 month post last treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Melasma</condition>
  <arm_group>
    <arm_group_label>Revlite Laser System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Revlite Laser System for the Treatment of Melasma</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Revlite Laser System</intervention_name>
    <description>Revlite Laser System for the Treatment of Melasma</description>
    <arm_group_label>Revlite Laser System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with Fitzpatrick Skin Type III-VI

          -  Subjects with mixed (epidermal and dermal) type melasma diagnosed by Wood's Lamp.

          -  Subjects who are over the age of 18 years of age

          -  The subject is willing and able to comply with study instructions and return to the
             clinic for required visits.

          -  The subject's melasma has persisted for greater than 6 months

        Exclusion Criteria:

          -  The subject is female and pregnant, has been pregnant within the last 3 months, is
             currently breast feeding or planning a pregnancy during the study period.

          -  The subject has a history of cutaneous photosensitization, porphyria, and
             hypersensitivity to porphyrins or photodermatosis.

          -  The subject has any skin pathology or condition that could interfere with the
             evaluation or requires the use of interfering topical or systemic therapy.

          -  The subject has an uncorrected coagulation defect or is currently using
             anti-coagulation medication (including but not limited to heavy aspirin therapy).

          -  The subject has any condition which, in the investigator's opinion, would make it
             unsafe for the subject to participate in this research study.

          -  The subject is currently enrolled in an investigational drug or device trial, or has
             received an investigational drug or been treated with an investigational device within
             30 days prior to entering this study.

          -  The subject has used photosensitizing drugs (e.g., Declomycin, sulfa antibiotics,
             phenothiazines, etc.) within a timeframe where photosensitization from these drugs may
             still be present.

          -  The subject has the need to be exposed to artificial tanning devices or excessive
             sunlight during the trial.

          -  The subject has had prior treatment with parenteral gold therapy (gold sodium
             thiomalate).

          -  The subject has Diabetes Type 1 or 2.

          -  The subject has a sensitivity to hydroquinone or Retin-A.

          -  The subject has evidence of a compromised immune system or hepatitis.

          -  Has had microdermabrasion in past 3 months, other laser or Intense Pulsed Light
             treatment or chemical peels to the face in past 6 months, injectable fillers, topical
             retinoids, over-the-counter anti-aging products past 2 weeks.

          -  Has a history of keloids or hypertrophic scarring

          -  Has permanent make-up and/or is unwilling to refrain from using semi-permanent
             cosmetics during study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Krantz</last_name>
    <role>Study Director</role>
    <affiliation>Cynosure, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NY Laser and Skin Care</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2014</study_first_submitted>
  <study_first_submitted_qc>April 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2014</study_first_posted>
  <last_update_submitted>July 29, 2015</last_update_submitted>
  <last_update_submitted_qc>July 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

